At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GRI GRI BIO INC
Market Closed 01-03 16:00:00 EST
0.9070
+0.0570
+6.71%
盘后0.8800
-0.0270-2.98%
19:59 EST
High0.9200
Low0.8400
Vol338.93K
Open0.8600
D1 Closing0.8500
Amplitude9.41%
Mkt Cap8.10M
Tradable Cap8.09M
Total Shares8.93M
T/O296.01K
T/O Rate3.80%
Tradable Shares8.92M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
GRI Bio announces issuance of decision to grant for European patent on GRI-0803
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.